Breaking News

Cambrex Expands Peptide Manufacturing Capabilities in Massachusetts

The company expands its API facility in Waltham, MA, to support the development and manufacturing of peptide therapies.

By: Rachel Klemovitch

Assistant Editor

Cambrex, a global contract development and manufacturing organization (CDMO), announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts, to further support the development and manufacturing of peptide therapies. The new GMP manufacturing suite increases the overall facility footprint by 20%. It includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materia...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters